|Day Low/High||40.43 / 40.99|
|52 Wk Low/High||29.39 / 47.82|
Following Wednesday's event, Leerink analyst Ami Fadia said she is 'incrementally more positive' on the drugmaker's pipeline and diversified business model and moved her rating to outperform.
The drug company generates about 60% of revenue outside the U.S.
While more than half the states in the U.S. have passed time limits on opioid prescription as a way to battle the epidemic, the AMA says that should be left up to the doctor and patient.
The pharmaceutical firm will conduct its investor day in New York City on April 11.
- Approval complements growing portfolio of cost-saving antiretroviral medications available to patients in the U.S., including recently announced Symfi Lo™ and Cimduo™
- Mitomycin for Injection is available to Mylan's hospital and other institutional customers -
Brent Saunders spoke at the Barclays healthcare conference, a few weeks after Mylan and Revance Therapeutics said they were teaming up on a proposed biosimilar of Allergan's Botox.
A massive price-fixing lawsuit brought by 45 states against a group of generic drug producers as well as a changing of the guard at the Food and Drug Administration may lead to changes in the generic drug sector.
Here's what you need to know now for Tuesday, March 6.
Morgan Stanley analyst David Risinger is upbeat about the drugmaker's generic drug growth prospects in the U.S.
Senator Tina Smith wants some answers from a group of Big Pharma companies about how the new cash flowing from the corporate tax break will be spent.
This is the exact type of strength we are looking for and recoups some of the cash we used earlier this morning.
- FDA recently approved Symfi Lo™, a three-drug single-tablet antiretroviral (ARV) regimen, and Cimduo™, a double combination, for HIV treatment
Mylan and Revance Therapeutics say they have teamed up to develop and commercialize a proposed biosimilar or copy of Allergan's popular Botox, potentially ratcheting up pressure on the drugmaker.
The pharmaceutical company unveiled a collaboration and license pact with Revance Therapeutics to develop and commercialize a proposed biosimilar or copy of Allergan's Botox.
Nucor looks to gain on the expected tariffs announcement, while separately we're downgrading Allergan.
The most recent short interest data has been released for the 02/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Allergan's losing streak in a bid to stash patent rights protecting cash cow Restasis remains intact as the U.S. Patent Trial and Appeal Board rejects a move to dismiss a challenge brought by a trio of pharma companies.
U.S. Patent Trial and Appeal Board denies St. Regis Mohawk Tribe's motion to terminate Restasis patent challenge
Mylan Board Nominates Pauline van der Meer Mohr for Election to Board of Directors
The Atlanta-based company has five directors who have served beyond the average tenure of 8.2 years.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.